The benefits of co-targeting PAK1 signaling with other chemotherapeutic agents have also been shown to improve the therapeutic outcome of pancreatic cancers [173,174] and decrease pancreatic cancer cell resistance to treatments [175]. Here, PAK1 is linked to pancreatic neoplasm.